2004
Targeting High-Risk Young Patients for Statin Therapy
Search citation statements
Paper Sections
Select...
7
0
0
0
Citation Types
0
2
0
0
Year Published
2004
2017
Publication Types
Select...
7
Relationship
0
7
Authors
Journals
Cited by 7 publications
(2 citation statements)
References 14 publications
0
2
0
0
“…23 Regarding possible effects on growth and maturation, the current data are reassuring in that no clinically relevant effects have been observed. 8,9,24 Again, the short duration of the available clinical trials is a concern; possible adverse effects on growth and/or maturation may not be seen in trials lasting 2 years or less. Use of statins in females of childbearing age should be avoided because we have no systematic data on the incidence of birth defects while taking these drugs during pregnancy.…”
Section: Pediatric Issues and Concernsmentioning
confidence: 99%
“…23 Regarding possible effects on growth and maturation, the current data are reassuring in that no clinically relevant effects have been observed. 8,9,24 Again, the short duration of the available clinical trials is a concern; possible adverse effects on growth and/or maturation may not be seen in trials lasting 2 years or less. Use of statins in females of childbearing age should be avoided because we have no systematic data on the incidence of birth defects while taking these drugs during pregnancy.…”
Section: Pediatric Issues and Concernsmentioning
confidence: 99%
“…1 Lifestyle changes alone may have a minimal impact on this genetic dyslipidemia, and the more potent options of drugs or blood apheresis to remove LDL have their own issues. 2 After a number of clinical trials that have reported significant coronary risk reductions, there can be no question that use of the lipid medications called statins must be considered as part of the treatment of high-risk adults, such as those who present with FH.…”
mentioning
confidence: 99%
